Nimacimab Enhances Incretin Therapies in DIO Mouse Model

Nimacimab combined with lower, more tolerable doses of incretin agonists may offer a better-tolerated and more durable option for long-term maintenance in chronic weight management.

Released January 28, 2026

Working with Halozyme ENHANZE® Technology for Higher Dosing

Skye-Halozyme partnership aims to co-formulate nimacimab + proven ENHANZE® technology, unlocking rapid, high-volume subcutaneous delivery with reduced pain and improved absorption for obesity treatment.

Released January 4, 2026

Using Arecor’s Arestat Technology to Increase Drug Dosing

Partner Arecor focused on achieving higher-concentration nimacimab using cutting-edge Arestat technology to enable simple, low-viscosity subcutaneous auto-injector delivery.

Released January 4, 2026

Unlocking Solutions to Deliver Higher Doses

Obesity-treating antibodies can require massive doses (eg. bimagrumab and MariTide). Skye is working toward subcutaneous delivery of higher-dose nimacimab without typical viscosity or high-volume injection hurdles.

Released January 4, 2026

ObesityWeek Presentation: Additional P2a Study Data

Obesity specialist Louis Aronne, MD, highlights CB1 inhibitor weight loss, weight rebound (after therapy discontinuation) and waist circumference in new data from Skye’s CBeyond trial.

Released November 7, 2025

CBeyond P2a Data: Nimacimab as Mono and Combination Therapy

Phase 2a topline data highlights nimacimab as monotherapy and a combo with a GLP-1 therapeutic, semaglutide, with weight loss, tolerability and safety outcomes.

Released October 6, 2025

Nimacimab P1b Safety and Tolerability Data

Skye presents a summary of safety, tolerability, and pharmacokinetic data from the Phase 1b of nimacimab at diabetes/obesity conference.

Released September 19, 2025

Review: Preclinical Data and Unmet Needs for Obesity Therapeutics

Skye’s CEO and CMO get perspectives from three obesity specialists regarding new preclinical results and imminent CBeyond Phase 2a clinical trial data.

Released September 5, 2025

Reviewing Component Mechanisms of Peripheral CB1 Inhibitor Antibody

Skye’s CMO and CSO discuss key differentiating mechanistic components of its peripherally-restricted CB1-inhibiting antibody, nimacimab.

Released September 4, 2025